GAPLINC is a predictor of poor prognosis and regulates cell migration and invasion in osteosarcoma

Abstract

Gastric adenocarcinoma predictive long intergenic non-coding (GAPLINC) is a novel long non-coding RNA (lncRNA) and has been found to function as an oncogenic lncRNA in gastric cancer, colorectal cancer, and bladder cancer. The expression status and biological function of GAPLINC in osteosarcoma are still unknown. Thus, we analyzed the association between GAPLINC expression and clinicopathological characteristics in osteosarcoma clinical samples, and conducted loss-of-function study in osteosarcoma cell lines. In our results, GAPLINC expression is elevated in osteosarcoma tissues and cell lines, and correlated with advanced Enneking stage, present distant metastasis, and poor histological grade. Survival analyses indicated that GAPLINC expression was negatively associated with overall survival, and GAPLINC high-expression was an independent risk factor in osteosarcoma patients. The in vitro studies showed knockdown of GAPLINC depressed osteosarcoma cell migration and invasion via inhibiting CD44 expression, but no effect on cell proliferation. In conclusion, GAPLINC may serve as a potential biomarker for predicting prognosis and developing therapy for osteosarcoma.

CD44 In Sarcomas: A Comprehensive Review and Future Perspectives

“…The overexpression of miR-199a-3p in KHOS and U-2OS inhibited CD44 mRNA levels and significantly increased the sensitivity of these cells to doxorubicin (144). In other studies, in vitro knockdown of the oncogenic long noncoding RNA GAPLINC (Gastric adenocarcinoma predictive long intergenic non-coding) in HOS and Saos-2 osteosarcoma cell lines, reduced migration and invasion by inhibiting considerably CD44 expression, although it does not impair cell proliferation (145). In summary, these studies suggest that the CD44-miR-199a-3p axis and GAPLINC regulation are relevant regulators in the development of metastasis, tumor recurrence, and drug resistance in osteosarcoma cells mediated by CD44.…”

Effects of Lidocaine and Ropivacaine on Gastric Cancer Cells Through Down-regulation of ERK1/2 Phosphorylation In Vitro

“…Conventional therapeutic methods for gastric cancer are target-specific drug treatment (3), surgical excision (4), radiotherapy or chemotherapy (5). After surgery, the recurrence and metastasis of gastric cancer are pressing issues, and are complicated processes involved a series of events (6,7), such as tumor heterogeneity, and epigenetic changes (8,9). It has been confirmed that circulating tumour cells with the ability to diffuse and metastasize are a prime prognostic marker for cancer recurrence (10,11).…”

Role of LncRNA in Rheumatoid Arthritis

“…There is a negative correlation observed between the expression of GAPLINC and the miRNAs [20]. Also, GAPLINC may be a new therapeutic target for RA [21].…”